Physician profile
David Binder
NPI 1487655734
$1,939.55
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $293 · 2021: $485 · 2022: $310 · 2023: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.40 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Exeltis, USA INC. | $186.16 | 2019-2023 | Slynd |
| Therapeuticsmd, INC. | $171.09 | 2019-2022 | |
| Coopersurgical, INC. | $95.99 | 2019-2023 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $94.73 | 2019-2022 | |
| Evofem Biosciences, INC. | $88.17 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.35 | 2019-2021 | |
| Daiichi Sankyo INC. | $71.46 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $70.87 | 2022-2023 | |
| Avion Pharmaceuticals | $54.91 | 2019-2022 | |
| Millicent US INC | $54.70 | 2019-2020 | |
| Agile Therapeutics, INC. | $44.05 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $43.64 | 2019 | |
| Pfizer INC. | $36.85 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $29.49 | 2023 | Myfembree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $29.24 | 2019 | |
| Astellas Pharma US INC | $27.37 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $26.31 | 2019-2021 | |
| Scynexis, INC. | $22.07 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $14.61 | 2023 | Vivjoa |
| Myovant Sciences INC. | $14.44 | 2022 | |
| Hologic Sales and Service, LLC | $13.73 | 2019 | |
| Lilly USA, LLC | $13.14 | 2019 | |
| Allergan, INC. | $11.73 | 2019 | |
| Lupin INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Binder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.